Dr. Kenneth C. Chern, MD

Dr. Chern practices at Mid Peninsula Endoscopy Center in Burlingame, California.

Dr. Chern's NPI, 1790880078, was assigned on September 13, 2006. Dr. Chern graduated from Feinberg School of Medicine in 1992. Dr. Chern's California license number on file is G82279.

Dr. Chern's primary practice is Mid Peninsula Endoscopy Center, at 1720 El Camino Real, Suite 100, Burlingame, CA 94010. The practice phone is (650) 373-1970.

Dr. Chern's primary practice is Mid Peninsula Endoscopy Center in Burlingame, California. Dr. Chern is also affiliated with Mills-Peninsula Medical Center. Dmand AI also links Dr. Chern to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chern practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Chern's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Chern is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Chern's licenses on file in 4 states: California, Oregon, Massachusetts and Washington.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Chern treats.

CMS data shows 3,924 Medicare services from Dr. Chern across 20 procedure codes in 2024, for 897 Medicare patients. Medicare paid $291,308 for them.

CMS counts 897 Medicare patients who saw Dr. Chern in 2024. The largest group is 75 to 84, with 393 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.10, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chern's median patient age at 74, with 55% women.

In 2024, Dr. Chern wrote 1,036 Medicare Part D claims for 248 patients. 50% of them were for generic drugs. CMS names the drug for 931 of them, across 17 drugs with 11 or more claims each, at $63,947 in total drug cost. In 2023, CMS named 1,028 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Chern for performance year 2024, reported as part of a group. Dr. Chern accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 143 procedures of cataract surgery by Dr. Chern, more than 79% of the clinicians it reports for that procedure.

Dmand AI links 12 papers to Dr. Chern. The most frequent topics are Cornea, Acquired Immunodeficiency Syndrome and Antiviral Agents. Dr. Chern has published most often in Am J Ophthalmol. Dr. Chern's most frequent co-authors are Diane B. Chandler, DO, Emmett T. Cunningham, MD, MPH, PhD and Baruch D. Kuppermann, MD.

Dmand AI links Dr. Chern to 1 clinical trial. Conditions studied include Cataract and Lens Diseases. Open Payments lists research payments to Dr. Chern that name 1 trial.

CMS Open Payments shows 66 general payments to Dr. Chern from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Valeant Pharmaceuticals International paid the most, $5,313. It also lists 3 research payments totaling $35,931 in 2019, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Chern.

Dr. Chern graduated from Feinberg School of Medicine in 1992. Dr. Chern is a member of AAO.

Dr. Chern is in network with 12 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.